Fluticasone Furoate
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Fluticasone Furoate: Atopic eczema
One-Sentence Summary
Fluticasone furoate is an inhaled corticosteroid, originally used for asthma and allergic rhinitis. The TxGNN model predicts it may be effective for atopic eczema, but this is a model-only prediction with 0 clinical trials and no directly relevant publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Atopic eczema |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this report. Fluticasone furoate is a glucocorticoid. Topical corticosteroids are a standard treatment for eczema because of their anti-inflammatory and immunosuppressive effects, so the prediction is plausible at the drug-class level.
The original indications (asthma, allergic rhinitis) and atopic eczema are all allergic or atopic inflammatory conditions, which may explain the very high model score. However, the only available Australian product is an oral inhalation powder, not a dermal formulation. No studies were found of this drug used for atopic eczema. The score most likely reflects glucocorticoid class similarity rather than drug-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 19571596 | 2009 | Review | Neuroimmunomodulation | Intranasal corticosteroids and adrenal suppression. Allergic rhinitis often coexists with atopic dermatitis, and the review focuses on assessing HPA-axis effects. This is a safety topic, not evidence of efficacy in eczema. |
| 40066386 | 2025 | Case report | Indian J Otolaryngol Head Neck Surg | Allergen immunotherapy in a patient with autoimmune disease. Atopic dermatitis is mentioned only as a possible application of immunotherapy, and the report does not address fluticasone furoate. |
Neither publication tests fluticasone furoate for atopic eczema.
Australia Market Information
| ARTG Number | Product Name | Dosage Form |
|---|---|---|
| ARTG 11719T | Arnuity Ellipta | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses |
Safety Considerations
Product-specific warnings, contraindications and interaction data were not available. Please refer to the TGA-approved Product Information (PI) for safety information.
The knowledge graph links fluticasone furoate to the following conditions as contraindications. These are not taken from label text and should be checked against the PI:
- Infections: measles, varicella zoster infection, herpes simplex virus keratitis, fungal infectious disease, dermatophytosis, pulmonary tuberculosis, parasitic infection, infectious disease in general
- Adrenal conditions: adrenocortical insufficiency, Addison disease, adrenal gland hyperfunction, Cushing syndrome
- Eye conditions: ocular hypertension, glaucoma
- Respiratory tract conditions: lower respiratory tract disease, upper respiratory tract disease, paranasal sinus disease, nasal cavity disease
A review in the retrieved literature also raises adrenal (HPA-axis) suppression as a concern with intranasal corticosteroids. This would matter for any extended or higher-exposure use.
Conclusion and Next Steps
Decision: Hold
Rationale: The atopic eczema prediction rests only on a high model score and glucocorticoid class plausibility. There are no trials, no relevant efficacy literature, and no dermal formulation in Australia.
For context, the data compiled for this report show stronger evidence for obstructive lung disease (COPD). That evidence comes mainly from combination products such as fluticasone furoate/vilanterol and fluticasone furoate/umeclidinium/vilanterol, and it is largely an established use rather than novel repurposing.
To proceed, the following is needed:
- Preclinical or early clinical evidence of efficacy and skin safety of fluticasone furoate in atopic eczema
- A feasible dermal formulation, or a justification for the current inhaled product
- Detailed mechanism of action data
- Review of the PI for warnings, contraindications and interactions, including adrenal suppression and infection risk
- Comparison against established topical corticosteroids for atopic eczema
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.